Volume 19, Issue 6, Pages (December 2003)

Slides:



Advertisements
Similar presentations
Volume 33, Issue 2, Pages (August 2010)
Advertisements

Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation by Juliette Mouriès, Gabriel Moron, Géraldine Schlecht,
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites 
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Volume 32, Issue 4, Pages (April 2010)
Following the Development of a CD4 T Cell Response In Vivo
Wei Hu, Ty Dale Troutman, Ramakrishna Edukulla, Chandrashekhar Pasare 
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
Volume 31, Issue 2, Pages (August 2009)
Volume 16, Issue 2, Pages (February 2002)
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Volume 30, Issue 4, Pages (April 2009)
Volume 137, Issue 3, Pages (September 2009)
Volume 18, Issue 5, Pages (May 2003)
Ananda W Goldrath, Michael J Bevan  Immunity 
Volume 140, Issue 7, Pages (June 2011)
Volume 21, Issue 1, Pages (July 2004)
Volume 35, Issue 6, Pages (December 2011)
Norito Katoh, Fujiko Soga, Takeshi Nara, Koji Masuda, Saburo Kishimoto 
Volume 25, Issue 5, Pages (November 2006)
Volume 17, Issue 12, Pages (December 2016)
Volume 29, Issue 2, Pages (August 2008)
NKT Cells Inhibit the Onset of Diabetes by Impairing the Development of Pathogenic T Cells Specific for Pancreatic β Cells  Lucie Beaudoin, Véronique.
Volume 33, Issue 2, Pages (August 2010)
Volume 31, Issue 2, Pages (August 2009)
Volume 7, Issue 4, Pages (October 2016)
Volume 18, Issue 3, Pages (March 2003)
Volume 27, Issue 2, Pages (August 2007)
Volume 132, Issue 1, Pages (January 2007)
Volume 41, Issue 1, Pages (July 2014)
Volume 8, Issue 6, Pages (June 1998)
Volume 29, Issue 5, Pages (November 2008)
Volume 29, Issue 3, Pages (September 2008)
Volume 28, Issue 6, Pages (June 2008)
Volume 17, Issue 1, Pages (July 2002)
Volume 24, Issue 2, Pages (February 2006)
B7.2−/− Mature Dendritic Cells Generate T-Helper 2 and Regulatory T Donor Cells in Fetal Mice after In Utero Allogeneic Bone Marrow Transplantation  Swati.
Volume 29, Issue 6, Pages (December 2008)
Volume 36, Issue 2, Pages (February 2012)
Volume 25, Issue 3, Pages (September 2006)
Volume 16, Issue 5, Pages (May 2002)
Volume 33, Issue 4, Pages (October 2010)
Volume 22, Issue 2, Pages (February 2005)
Cécile Bouneaud, Philippe Kourilsky, Philippe Bousso  Immunity 
Volume 27, Issue 2, Pages (August 2007)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Volume 32, Issue 5, Pages (May 2010)
Volume 33, Issue 3, Pages (September 2010)
Volume 135, Issue 3, Pages (September 2008)
Volume 43, Issue 2, Pages (August 2015)
Volume 38, Issue 3, Pages (March 2013)
Volume 29, Issue 5, Pages (November 2008)
Human CD4+ T Lymphocytes with Remarkable Regulatory Functions on Dendritic Cells and Nickel-Specific Th1 Immune Responses  Andrea Cavani, Francesca Nasorri,
Chie Kudo-Saito, Hiromi Shirako, Tadashi Takeuchi, Yutaka Kawakami 
Volume 126, Issue 6, Pages (September 2006)
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley  Kidney International 
Volume 30, Issue 4, Pages (April 2009)
Volume 28, Issue 5, Pages (May 2008)
Volume 131, Issue 6, Pages (December 2006)
Volume 38, Issue 2, Pages (February 2013)
Volume 4, Issue 6, Pages (June 1996)
Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand  Yelena Glinka,
Notch 1 Signaling Regulates Peripheral T Cell Activation
Volume 35, Issue 1, Pages (July 2011)
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo by Holger Hackstein, Timucin Taner,
Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites 
Volume 29, Issue 3, Pages (September 2008)
Presentation transcript:

Volume 19, Issue 6, Pages 877-889 (December 2003) CD40 Ligation Releases Immature Dendritic Cells from the Control of Regulatory CD4+CD25+ T Cells  Pau Serra, Abdelaziz Amrani, Jun Yamanouchi, Bingye Han, Shari Thiessen, Toshihiro Utsugi, Joan Verdaguer, Pere Santamaria  Immunity  Volume 19, Issue 6, Pages 877-889 (December 2003) DOI: 10.1016/S1074-7613(03)00327-3

Figure 1 Diabetogenicity and Function of 8.3-CD8+ Cells in the Presence of CD154−/−CD4+ Cells (A) Incidence of diabetes in female 8.3-NOD.RAG-2+/CD154+ (n = 214) versus 8.3-NOD.RAG-2+/CD154−/− mice (n = 59; P < 0.0001), and 8.3-NOD.RAG-2−/−/CD154+ (n = 106) versus 8.3-NOD.RAG-2−/−/CD154−/− mice (n = 63). (B) Insulitis scores of 8.3-NOD-RAG-2+/CD154+ (n = 4; 6 weeks) versus 8.3-NOD.RAG-2+/CD154−/− mice (11 10- to 11-week-old plus 6 20- to 31-week-old; no differences in insulitis scores were observed between the two age groups) (P < 0.0001). (C) Proliferation of splenic CD8+ cells against NRP-A7-pulsed (1 μM) NOD DCs. Background responses (against TUM, 1 μM) were subtracted. (D) Secretion of IFN-γ by 8.3-CD8+ cells against peptide-pulsed DCs. (E) Cytotoxicity of NRP-A7-differentiated 8.3-CD8+ cells against NRP-A7- or TUM-pulsed RMA-SKd cells (1 μM) at a 1:10 target:effector ratio. (F) Incidence of diabetes in 8.3/RIP-B7.1-NOD.RAG-2+/CD154−/− (n = 17) and 8.3/RIP-B7.1-NOD.RAG-2+/CD154+ mice (n = 8). Bars in (B)–(E) show the standard error of the means. Immunity 2003 19, 877-889DOI: (10.1016/S1074-7613(03)00327-3)

Figure 2 Function and Phenotype of DCs in NOD.CD154−/− Mice (A) Proliferation of naive, CFSE-labeled 8.3-CD8+ cells in the PLNs and MLNs of NOD or NOD.CD154−/− mice (8 to 12 weeks old) 6 days after transfer. (B) Proliferation of naive 8.3-CD8+ cells against peptide-pulsed (1 μM) splenic or PLN DCs (5 × 103) or immature bone marrow-derived DCs (104) (8- to 13-week-old donors). (C) Downregulation of DC markers on PLN DCs of NOD.CD154−/− versus NOD mice. DCs were purified from PLN cells pooled from several mice (>20 weeks old). Mfi, mean fluorescence intensity. (D) IFN-γ secretion by naive 8.3-CD8+ cells against splenic or PLN-derived DCs (5 × 103; peptide-pulsed) (>20-week-old donors). Immunity 2003 19, 877-889DOI: (10.1016/S1074-7613(03)00327-3)

Figure 3 NOD.CD154−/− Mice Export Functional CD4+CD25+ Cells to the Periphery (A) Percentage of CD4+ cells that are CD25+ in the thymus, MLN, and PLN of NOD (thymus, spleen, and MLN: n = 4; PLN: n = 8) and NOD.CD154−/− mice (n = 5) (age of PLN NOD and NOD.CD154−/− donors: 11 ± 2 and 13 ± 3 weeks, respectively). *, P<0.007. (B) Activated CD4+CD25+, but not CD4+CD25− cells from NOD.CD154−/− mice (2 × 105) inhibit IFN-γ secretion by naive 8.3-CD8+ cells (2 × 104) in response to NRP-A7 peptide-pulsed DCs (1 μM) over a range of DC numbers. (C) Activated CD4+CD25+ but not CD4+CD25− cells (0–2 × 105) inhibit 8.3-CD8+ cell responses (2 × 104) to NRP-A7-pulsed DCs (104) over a range of CD8+:CD4+ ratios. In (B) and (C), background responses to the control peptide TUM were subtracted. DCs were generated from bone marrow and plated as immature cells. CD4+CD25+ cells were purified from pooled MLNs and spleen. Immunity 2003 19, 877-889DOI: (10.1016/S1074-7613(03)00327-3)

Figure 4 Function of CD4+CD25+ Cells from NOD and NOD.CD154−/− Mice (A) Splenic/MLN CD4+CD25+ cells (105; from 13- to 16-week-old mice) do not proliferate in response to anti-CD3-coated beads (105) in the absence of rIL-2. (B) Splenic/MLN CD4+CD25+ cells (from 13- to 16-week-old mice) proliferate moderately in response to rIL-2 in the presence of irradiated NOD splenocytes (105), and this response is enhanced by anti-GITR Abs. (C) Cytokine profiles of splenic/MLN CD4+CD25+ and CD4+CD25− cells. Freshly isolated cells (105) were stimulated with anti-CD3-coated beads (105) in the absence (upper panels) or presence of rIL-2 (lower panels). Supernatants collected at 48 hr were assayed for various cytokines. Immunity 2003 19, 877-889DOI: (10.1016/S1074-7613(03)00327-3)

Figure 5 NOD and NOD.CD154−/− CD4+CD25+ Cells Downregulate DC Function In Vitro and Inhibit 8.3-CD8+ Cells Indirectly via DCs (A) Activated CD4+CD25+ cells (2 × 105) from NOD and NOD.CD154−/− mice (8- to 15-week-old) cannot inhibit 8.3-CD8+ responses (2 × 104) induced by NRP-A7/Kd or IGRP206-214/Kd monomers. Monomers could not elicit IFN-γ secretion by CD4+CD25+ cells (not shown). (B) Immature bone marrow-derived DCs cultured with NOD CD4+CD25+ cells express lower levels of several DC markers as compared to DCs cultured with NOD CD4+CD25− cells. (C) Splenic CD4+CD25+ cells from NOD.CD154−/− mice inhibit the upregulation of markers on immature bone marrow-derived DCs. CD11c+ DCs were phenotyped after a 7 day culture with GM-CSF and IL-4, or cultured alone or in the presence of activated CD4+CD25+ or CD4+CD25− cells (at 1:1 ratio) for 56 hr. (D) Splenic CD4+CD25+ cells inhibit DC maturation. Left and middle panels: bone marrow-derived DCs were activated with CpG DNA or LPS, washed, cultured with activated NOD CD4+CD25+ cells as in (B), and analyzed by FACS. Panels show levels of CD11c and CD40 on CD11c+ cells. Right panels: immature DCs were cultured with activated NOD CD4+CD25+ cells, stimulated with CpG DNA, and analyzed. Histograms correspond to live CD4− cells. (E) Splenic CD4+CD25+ cells cannot inhibit the APC activity of CpG- or LPS-activated DCs. Immunity 2003 19, 877-889DOI: (10.1016/S1074-7613(03)00327-3)

Figure 6 NOD CD4+CD25+ Cells Inhibit DC-Induced Activation of 8.3-CD8+ Cells in a CTLA-4-Dependent, but IL-4-, IL-10-, and TGF-β1-Independent Manner CD4+CD25+ cells from NOD (A and B) or NOD.IL4−/− and NOD.IL-10−/− mice (C) (10- to 16-week-old) were cocultured with NRP-A7-pulsed DCs and 8.3-CD8+ cells in the presence or absence of blocking or control Abs. For TGF-β1, similar results were obtained with anti-human TGF-β1 chicken antiserum and the mAb 2G7 (data shown correspond to 2G7). Immunity 2003 19, 877-889DOI: (10.1016/S1074-7613(03)00327-3)